Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSLN CAR NK cells
- Development stage
- Preclinical
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MSLN CAR NK cells are an experimental cell-based immunotherapy consisting of natural killer (NK) cells engineered to express a chimeric antigen receptor (CAR) specific for mesothelin (MSLN). Mesothelin is a cell surface glycoprotein overexpressed in various solid tumors—including pancreatic ductal adenocarcinoma, ovarian cancer, and mesothelioma—as well as in specific subtypes of acute myeloid leukemia (AML), such as KMT2A-rearranged AML. The therapy utilizes the innate cytotoxic potential of NK cells, which are redirected by the CAR (often incorporating 4-1BB and CD3ζ signaling domains) to recognize and lyse MSLN-expressing cells. Compared to CAR-T cell therapies, CAR-NK cells are being explored for their potentially superior safety profile, including a lower risk of cytokine release syndrome and the potential for off-the-shelf allogeneic use.
- Other names
- Mesothelin-targeting Chimeric Antigen Receptor Natural Killer cellsMSLN-directed CAR NK cellsanti-MSLN CAR-NK
02
Targets
Mesothelin
Beyond the preview
Go deeper on MSLN CAR NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSLN CAR NK cells.